Ability Pharmaceuticals is a clinical-stage biopharmaceutical company committed to develop first-in-class therapies that address unmet medical needs in the oncology space. ABTL0812, the most advanced asset, has finished with very positive results a phase 2a clinical trial as first-line therapy in endometrial cancer and in squamous NSCLC in combination with paclitaxel and carboplatin. The study included leading institutions in Spain and France (Vall d’Hebron Institut d’Oncologia – VHIO, Institut Gustave Roussy, Centre Léon Bérard). AbilityPharma's next goal is to conduct an international multicenter, double-blind, placebo-controlled phase 2b clinical trial in pancreatic cancer to investigate ABTL0812 in combination with FOLFIRINOX chemotherapy. The study will include reference centers in Spain, France, United States and Israel. ABTL0812 is the first cancer drug killing tumor cells through potent cytotoxic autophagy via inhibition of the Akt/mTOR axis, and the induction of robust endoplasmic reticular stress (ER Stress). Its unique mechanism of action was partially published at Clinical Cancer Research in December 2015 and fully characterized at Autophagy journal in May 2020. The compound is active as standalone treatment, it has synergy with chemotherapy, and it has synergy with anti PD1 therapies. The product has potential in several cancer types as first-line and maintenance therapy including lung, endometrial, pancreatic, breast, head and neck cancer, glioblastoma, cholangiocarcinoma and the pediatric cancer neuroblastoma. ABTL0812 has been granted Orphan Drug Designation for pancreatic cancer, neuroblastoma, and biliary tract cancer, by the US FDA and the European EMA. Development and marketing rights for Greater China granted to SciClone Pharmaceuticals, Inc. in a territorial license agreement were signed in April 2016.
Location: Spain, Catalonia, Cerdanyola del Vallès
Employees: 11-50
Total raised: $12.01M
Founded date: 2009
Investors 1
Date | Name | Website |
- | Fitalent | fitalent.e... |
Funding Rounds 3
Date | Series | Amount | Investors |
12.03.2024 | - | $7.65M | - |
27.12.2020 | - | $3M | - |
04.12.2018 | - | $1.36M | - |
Mentions in press and media 12
Date | Title | Description | Source |
13.03.2024 | AbilityPharma's Fight Against Cancer | AbilityPharma, a Barcelona-based biopharmaceutical company, secured a hefty EUR 7 million in funding... | parsers.vc... |
12.03.2024 | Spain-based AbilityPharma raises EUR 7 million in funding | Barcelona, Spain-based biopharmaceutical company focused on the development of innovative oral autop... | vcbay.news... |
11.03.2024 | AbilityPharma Raises €7M in Financing | AbilityPharma, a Barcelona, Spain-based biopharmaceutical company focused on the development of inno... | finsmes.co... |
29.12.2020 | SciClone se incorpora al capital de AbilityPharma, participa... | 29/12/2020 Nota de prensa SCICLONE SE INCORPORA AL CAPITAL DE ABILITYPHARMA, PARTICIPADA POR INVER... | webcapital... |
18.11.2020 | Ability Pharma, participada por Inveready, Fitalent, Sodena ... | 18/11/2020 ABILITY PHARMA, PARTICIPADA POR INVEREADY, FITALENT, SODENA Y EL CDTI, CIERRA UNA RONDA ... | webcapital... |
22.10.2020 | Ability Pharma, participada por Inveready, capta $1,9M de la... | 22/10/2020 ABILITY PHARMA, PARTICIPADA POR INVEREADY, CAPTA $1,9M DE LA FOOD & DRUG ADMINISTRAT... | webcapital... |
17.03.2020 | Ability Pharma, participada por Inveready, Everis y Sodena, ... | 17/03/2020 ABILITY PHARMA, PARTICIPADA POR INVEREADY, EVERIS Y SODENA, CAPTA €2,5M DE VARIOS INVERS... | webcapital... |
12.09.2019 | AbilityPharma cierra una ronda de €3,5M, acuden Inveready, G... | 12/09/2019 Nota de prensa ABILITYPHARMA CIERRA UNA RONDA DE €3,5 MILLONES, ACUDEN INVEREADY, GRUPO... | webcapital... |
14.12.2018 | Barcelona Startup News December 10 2018 – Barcinno | Hello and happy Monday! Before we begin, a big congrats to our friends at Drivinapp on securing a n... | barcinno.c... |
04.12.2018 | Ability Pharma cierra una ronda de más de €1,23M a través de... | 04/12/2018 Nota de prensa ABILITY PHARMA CIERRA UNA RONDA DE MÁS DE 1,23 MILLONES A TRAVÉS DE CAPI... | webcapital... |
Show more